0001104659-24-074995.txt : 20240626 0001104659-24-074995.hdr.sgml : 20240626 20240626083029 ACCESSION NUMBER: 0001104659-24-074995 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240625 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 241070700 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 tm2418261d1_8k.htm FORM 8-K
false 0001585608 0001585608 2024-06-25 2024-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 25, 2024 

 

JAGUAR HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36714 46-2956775
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer Identification No.)

 

200 Pine Street, Suite 400

San Francisco, California

 94104
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (415) 371-8300 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Title of each class Trading
Symbol(s)		 Name of each exchange on which
registered
Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Market

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously reported in its Current Report on Form 8-K filed on May 12, 2023, Jaguar Health, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price for the Company’s common stock for the last 30 consecutive business days was below the $1.00 per share minimum required for continued listing under Nasdaq Listing Rule 5550(a)(2). On June 25, 2024, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the minimum bid price deficiency had been cured and that Nasdaq had determined to continue the listing of the Company’s common stock on The Nasdaq Stock Market.

 

On June 26, 2024, the Company issued a press release with respect to the foregoing, a copy of which is furnished as Exhibit 99.1 hereto. 

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated June 26, 2024.
104   Cover Page Interactive Data File (embedded with the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JAGUAR HEALTH, INC.
     
  By: /s/ Lisa A. Conte
    Name: Lisa A. Conte
    Title: Chief Executive Officer & President
       
Date: June 26, 2024      

 

 

 

 EX-101.SCH 2 jagx-20240625.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 jagx-20240625_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 jagx-20240625_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-99.1 5 tm2418261d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

 

JAGX’s securities continue to be listed and traded on Nasdaq

 

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024

 

San Francisco, CA (June 26, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that Jaguar has regained compliance with Nasdaq’s minimum bid price requirement.

 

“We are very happy that Jaguar has regained compliance with Nasdaq. We consider our Nasdaq listing an asset of the Company,” said Lisa Conte, Jaguar’s president and CEO. “A Jaguar investor webcast held on or before July 23, 2024 will provide updates on Jaguar’s advancing cancer supportive care portfolio, and will include members of Jaguar’s scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.”

 

About the Jaguar Health Family of Companies

 

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer also is the subject of Napo’s phase 3 OnTarget clinical trial for preventive treatment of cancer therapy-related diarrhea (CTD). Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

 

For more information about: 

Jaguar Health, visit https://jaguar.health 

Napo Pharmaceuticals, visit www.napopharma.com 

Napo Therapeutics, visit napotherapeutics.com 

Magdalena Biosciences, visit magdalenabiosciences.com

 

Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram

 

 

 

 

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that Jaguar will report the results of the OnTarget trial on or before July 23, 2024, and the expectation that Jaguar will hold an investor webcast on or before July 23, 2024 regarding updates on the Company's cancer supportive care portfolio. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

Source: Jaguar Health, Inc.

 

Contact: 

hello@jaguar.health 

 

Jaguar-JAGX

 

 

 

 GRAPHIC 6 tm2418261d1_ex99-1img01.jpg GRAPHIC begin 644 tm2418261d1_ex99-1img01.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 25, 2024
Entity File Number 001-36714
Entity Registrant Name JAGUAR HEALTH, INC.
Entity Central Index Key 0001585608
Entity Tax Identification Number 46-2956775
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 200 Pine Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 415
Local Phone Number 371-8300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol JAGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jaguaranimalhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports jagx-20240625.xsd jagx-20240625_lab.xml jagx-20240625_pre.xml tm2418261d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2418261d1_8k.htm": { "nsprefix": "jagx", "nsuri": "http://jaguaranimalhealth.com/20240625", "dts": { "schema": { "local": [ "jagx-20240625.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "jagx-20240625_lab.xml" ] }, "presentationLink": { "local": [ "jagx-20240625_pre.xml" ] }, "inline": { "local": [ "tm2418261d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://jaguaranimalhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2418261d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2418261d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-074995-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-074995-xbrl.zip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�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end XML 18 tm2418261d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001585608 2024-06-25 2024-06-25 iso4217:USD shares iso4217:USD shares false 0001585608 8-K 2024-06-25 JAGUAR HEALTH, INC. DE 001-36714 46-2956775 200 Pine Street Suite 400 San Francisco CA 94104 415 371-8300 false false false false false Common Stock, Par Value $0.0001 Per Share JAGX NASDAQ